Inflammatory bowel disease
Therapeutic area
Immunology
Rare disease
No
- Definition
- A spectrum of small and large bowel inflammatory diseases of unknown etiology. It includes Crohn's disease, ulcerative colitis, and colitis of indeterminate type.
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Inflammatory bowel disease
- Therapeutic area
- Immunology
- inflammatory bowel disease
- IBD
- autoimmune bowel disorder
- inflammatory bowel disease
- Severity
- Moderate
- Genetic
- Hereditary
- Gastroenterology
- Immunology
- MONDO ID
- MONDO:0005265
- Parent condition
- MONDO:0003847
Related records
Broader conditions (9)
- Digestive system disorder
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Disease of genetic or genomic mechanism
- Hereditary disease
- Human disease
- Immune system disorder
- Intestinal disorder
Narrower conditions (71)
- ALPI-related inflammatory bowel disease
- Cap polyposis
- Chemical colitis
- Clostridium difficile colitis
- Colitis
- Collagenous colitis
- Crohn disease
- Crohn disease of the esophagus
- Crohn ileitis
- Crohn jejunitis
- Crohn jejunoileitis
- Crohn's colitis
- Cutaneous photosensitivity-lethal colitis syndrome
- Distal colitis
- Diversion colitis
- Eosinophilic colitis
- Food protein-induced allergic proctocolitis
- Gastroduodenal Crohn disease
- IL10-related early-onset inflammatory bowel disease
- Ileocolitis
Trials (1,606)
- 25-hydroxyvitamin D and Fatigue: The VITALITY Study
- 3D Laparoscopy Versus 2D Laparoscopy
- 90Second IBD for the Improvement of Self Efficacy and Quality of Life in Inflammatory Bowel Disease Patients
- 99mTc-rhAnnexin V-128 in Diagnosis of Spondyloarthritis
- A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
- A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
- A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
- A Brief Intervention to Improve Adherence in Teens With Inflammatory Bowel Disease
- A Clinical Study of SPH7854 Granules in Healthy Subjects.
- A Clinical Study on the Screening of Intestinal Biomarkers in IBD Patients With Depression
- A Clinical Study on The Use of DL-endopeptidase-producing Probiotics as an Adjunctive Therapy for Inflammatory Bowel Disease.
- A Clinical Study to Evaluate SM17 in Healthy Participants
- A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease
- A Comparison of Ultrasound Guided Transversus Abdominis Plane Nerve Block Techniques
- A Comprehensive Self-Management Intervention for Individuals With Inflammatory Bowel Disease
- A Database Study of Disease, Treatment Patterns and Healthcare Use in Children With Inflammatory Bowel Diseases in Korea
- A Development of Inflammatory Bowel Disease Pattern Identification Algorithm Using Case Series Data
- A Diagnostic Accuracy Study Testing Fecal Biomarkers In Comparison To Endoscopic Examination
- A Dietary Intervention Study on the Microbiome in Crohn's Disease Patients
- A Double Blind Study for the Treatment of Acute Ulcerative Colitis
Drugs in development (72)
- 2'-fucosyllactose Phase 1
- Adalimumab Phase 3
- Alicaforsen Phase 1
- Allopurinol Phase 1
- Amiselimod hydrochloride Phase 1
- Amitriptyline Phase 2
- Andrographolide Phase 3
- Atorvastatin Phase 2
- Azathioprine Phase 1
- Balsalazide disodium Phase 3
- BPC-157 Phase 2
- Brazikumab Phase 3
- Budesonide Phase 2
- Charcoal, activated Phase 3
- Cholecalciferol Phase 3
- CP-461 Phase 2
- Dapagliflozin Phase 2
- Declopramide Phase 2
- Dersalazine Phase 2
- Doramapimod Phase 2
Other linked drugs (13)
- Aminosalicylic acid
- Balsalazide
- Golimumab
- Methotrexate
- Nabilone
- Pantothenic acid
- Polyethylene glycol
- Prednisone
- Pyridoxine
- Reminertant
- Sulesomab
- Tamtuvetmab
- Upadacitinib